✨ Free AI Report
Cingulate Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cingulate Inc.
Company Research

Cingulate Inc.: Business Overview, Financials & Competitive Analysis

Cingulate Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Pre-commercialization biotech with FDA approval imminent for best-in-class ADHD treatment and proprietary delivery platform creating potential competitive moat. The FDA accepted the New Drug Application in October 2025 with a target PDUFA date of May 31, 2026, de-risking the lead candidate. The company secured an exclusive U.S. supply agreement with.

What is Cingulate Inc.'s industry? Cingulate Inc. (cingulate.com) operates in Biopharmaceuticals - ADHD Treatment. AskCyborg classifies Cingulate Inc. under Biopharmaceuticals - ADHD Treatment in its company registry.

Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technolog...

8/ 10Strong

Cyborg Score thesis

Pre-commercialization biotech with FDA approval imminent for best-in-class ADHD treatment and proprietary delivery platform...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - ADHD Treatment
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cingulate Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cingulate Inc.

AskCyborg analysts argue the bull and bear cases for Cingulate Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cingulate Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cingulate Inc. Overview

Pro stress-test →

Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD), with a pivotal FDA approval milestone expected in May 2026.

Strategic Profile

Pro stress-test →

The company reported positive Phase 3 results for CTx-1301 (dexmethylphenidate HCl) in pediatric ADHD, meeting its primary endpoint and showing dose-dependent improvements with rapid onset and sustained symptom relief up to 12 hours post-dose. Cingulate is preparing commercial infrastructure with partner Indegene, pending FDA approval, positioning itself for a competitive entry into the ADHD treatment market.

Competitive Landscape

Pro stress-test →

Cingulate competes in the ADHD treatment market against established players like Neuropathix (Adhansia XR), Shire/Takeda (Adzenys XR-ODT), and others. Its competitive advantage lies in the proprietary PTR platform enabling improved dosing schedules and full active-day coverage. The market opportunity is substantial given ADHD prevalence and patient dissatisfaction with existing regimens.

Industry Context

Cingulate Inc. operates in Biopharmaceuticals - ADHD Treatment.

Key facts

Founded: 2012 · Headquarters: Kansas City, Kansas

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cingulate Inc..

  • Positive Phase 3 pediatric ADHD data showed primary endpoint met with safety/tolerability consistent with stimulant class
  • Analyst consensus is "Strong Buy" with 12-month price target of $31.33, representing 415% upside from recent prices
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Closed $12M PIPE financing priced at $5.04/share with Falcon Creek Capital
  • January 2026Filed $200M mixed securities shelf registration
  • +2 moreTrack every material event for Cingulate Inc. as it happens. Explore monitoring →
Get alerted when Cingulate Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Adhansia XRLong-acting amphetamine combination for ADHD→Adzenys XR-ODTOrally disintegrating amphetamine formulation→ConcertaOsmotic release ADHD medication→

Compare Cingulate Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cingulate Inc. operates in Biopharmaceuticals - ADHD Treatment. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - ADHD Treatment research →
NEW · MCP server

Ask your AI assistant about Cingulate Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cingulate Inc. and its top competitor on Cyborg Score”
“What did Cingulate Inc. do this quarter?”
“Is Cingulate Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cingulate Inc. do?+
Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technolog...
What is Cingulate Inc.'s Cyborg Score?+
Cingulate Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cingulate Inc.'s main competitors?+
Named competitors include Adhansia XR, Adzenys XR-ODT, Concerta. The full competitive landscape is in the AskCyborg report.
How can I get the full Cingulate Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cingulate Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cingulate Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.